IP Library Granted Patent US 8,658,156
Granted Patent B2
US 8,658,156 · App. 12/667,653 · Granted Feb 25, 2014

Supplemention of maternal diet

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,658,156
App. No.
12/667,653
Granted
Feb 25, 2014
Kind
B2
Abstract

The use of probiotic bacteria in the manufacture of a composition for administration to a woman in at least the third trimester of pregnancy for prevention of gestational diabetes, normalizing plasma glucose concentration and/or increasing insulin sensitivity.

Claims (8)

1. A method for reducing the risk of developing gestational diabetes comprising administering to a woman in at least the third trimester of pregnancy in need thereof, a therapeutically-effective amount of a composition comprising probiotic bacteria Lactobacillus rhamnosus ATCC 53103 and Bifidobacterium lactis CNCM I-3446.

2. The method of claim 1 , wherein administration of the composition continues after delivery.

3. The method of claim 1 , wherein the probiotic bacteria is administered in a daily dose of between 10 5 to 10 12 colony forming units.

4. The method of claim 1 , wherein the probiotic bacteria is administered to the woman for the second and third trimesters of pregnancy.

5. The method of claim 1 , wherein the probiotic bacteria is administered for the full duration of the pregnancy.

6. The method of claim 1 , wherein the probiotic bacteria is administered in a daily dose of between 10 7 to 10 11 colony foaming units.

7. The method of claim 1 , wherein the composition further comprises a fat source that provides 20% to 30% of the total energy of the composition, a carbohydrate source that provides 40% to 80% of the total energy of the composition, and a protein source.

8. The method of claim 1 , wherein the woman to whom the composition is administered has a characteristic indicating increased risk of gestational diabetes, the characteristic selected from the group consisting of a pre-pregnancy body mass index over 25, an age over 40 years, gestational diabetes mellitus during a previous pregnancy, a previous delivery of a child who weighed more than 4500 g, detection of glucose in urine, suspect of macrosomic fetus in present pregnancy, and combinations thereof.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →